Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Accrued construction-in-progress

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:AccruedConstructionInProgressCurrent.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's accrued construction-in-progress.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's accrued construction-in-progress?
Jazz Pharmaceuticals (JAZZ) reported accrued construction-in-progress of $9.6M in Q1 2026.
How has Jazz Pharmaceuticals's accrued construction-in-progress changed year-over-year?
Jazz Pharmaceuticals's accrued construction-in-progress increased by 2.4% year-over-year, from $9.38M to $9.6M.
What is the long-term trend for Jazz Pharmaceuticals's accrued construction-in-progress?
Over 3 years (2022 to 2025), Jazz Pharmaceuticals's accrued construction-in-progress has grown at a 63.1% compound annual growth rate (CAGR), from $3.3M to $14.3M.